Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe

Shilpa Medicare Limited (BSE: 530549 | NSE: SHILPAMED) today announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited ("Shilpa Biologicals"), has entered into a co-development and supply agreement with Orion Corporation for intravenous(IV) nivolumab biosimilar referencing one of the world's most widely used cancer immunotherapies - bringing two companies together to widen patient access across Europe.

Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients across cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients - and to help health systems stretch every euro of their oncology budgets further.

In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe - underscoring the scale of the opportunity that high-quality biosimilars can unlock for patients and healthcare systems across the region.

Under the agreement, Orion will hold the exclusive right to register, market, distribute and sell the nivolumab biosimilar across Europe, and will act as the Marketing Authorisation holder in the territory. Shilpa Biologicals will lead product development and serve as the exclusive long-term commercial manufacturer and supplier for the European market from its advanced biologics facility in Dharwad, India. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments, in addition to supply revenue over the life of the partnership.

The deal marks another chapter in a fast-growing relationship. It follows the partners' earlier collaboration to bring Shilpa's Recombinant Human Albumin to Europe - and pairs Shilpa's end-to-end biologics development and manufacturing engine with Orion's deep European commercial reach, regulatory expertise and wellestablished distribution network.

"Extending our partnership with Orion into immuno-oncology is a defining moment for Shilpa Biologicals," added Vishnukant Bhutada, Managing Director, Shilpa Medicare. "It reflects the trust our partners place in our quality, our science and our ability to deliver complex biologics at scale - and it moves us closer to our mission of making advanced medicines affordable and accessible worldwide."

"We are pleased to add yet another product to our strategic partnership with Shilpa," said Satu Ahomäki, EVP Generics and Consumer Health, Orion Pharma. "This agreement is a step forward in our efforts to expand and strengthen our operations in hospital segment in Continental Europe, and an indication of the progress of the implementation of our division's strategy which aims to create everybody an access to affordable quality medicines."

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 598.55 as compared to the previous close of Rs. 573.75. The total number of shares traded during the day was 118583 in over 3580 trades.

The stock hit an intraday high of Rs. 614.90 and intraday low of 573.60. The net turnover during the day was Rs. 71106410.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 Pharmaceuticals ShilpaBiologicals Orion Partnership